Ines Dufait
Overview
Explore the profile of Ines Dufait including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geirnaert F, Kerkhove L, Montay-Gruel P, Gevaert T, Dufait I, De Ridder M
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796760
FLASH radiotherapy (FLASH RT) is an innovative modality in cancer treatment that delivers ultrahigh dose rates (UHDRs), distinguishing it from conventional radiotherapy (CRT). FLASH RT has demonstrated the potential to...
2.
Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, et al.
Cancer Immunol Immunother
. 2024 Jul;
73(9):167.
PMID: 38954010
Background: Radiotherapy (RT) synergizes with immune checkpoint blockade (ICB). CD1c(BDCA-1)/CD141(BDCA-3) myeloid dendritic cells (myDC) in the tumor microenvironment are indispensable at initiating effector T-cell responses and response to ICB. Methods:...
3.
Kerkhove L, Geirnaert F, Dufait I, De Ridder M
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612455
Recently, it was established that ferroptosis, a type of iron-dependent regulated cell death, plays a prominent role in radiotherapy-triggered cell death. Accordingly, ferroptosis inducers attracted a lot of interest as...
4.
Cornista A, Giolito M, Baker K, Hazime H, Dufait I, Datta J, et al.
Gastro Hep Adv
. 2023 Dec;
2(8):1103-1119.
PMID: 38098742
Cancer immunotherapy has become an indispensable mode of treatment for a multitude of solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to benefit from...
5.
Hebishy M, Shintouo C, Dufait I, Debacq-Chainiaux F, Bautmans I, Njemini R
Arch Gerontol Geriatr
. 2023 May;
113:105057.
PMID: 37207540
Cellular senescence (CS) is a permanent arrest of cell growth and exit of the cell cycle. It is an important tumor suppression mechanism and has a key role in wound...
6.
Kerkhove L, Geirnaert F, Rifi A, Law K, Gutierrez A, Oudaert I, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190291
xCT overexpression in cancer cells has been linked to tumor growth, metastasis and treatment resistance. Sulfasalazine (SSZ), an FDA-approved drug for the treatment of rheumatoid sarthritis, and inflammatory bowel diseases,...
7.
Van de Gucht M, Dufait I, Kerkhove L, Corbet C, de Mey S, Jiang H, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291844
Augmented de novo serine synthesis activity is increasingly apparent in distinct types of cancers and has mainly sparked interest by investigation of phosphoglycerate dehydrogenase (PHGDH). Overexpression of PHGDH has been...
8.
Schwarze J, Tijtgat J, Awada G, Cras L, Vasaturo A, Bagnall C, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36113895
Background: Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC)...
9.
Kalus P, De Munck J, Vanbellingen S, Carreer L, Laeremans T, Broos K, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563257
Recently, a paradigm shift has been established for oncolytic viruses (OVs) as it was shown that the immune system plays an important role in the specific killing of tumor cells...
10.
de Mey S, Dufait I, De Ridder M
Front Oncol
. 2021 Nov;
11:761901.
PMID: 34778082
Although radiotherapy is given to more than 50% of cancer patients, little progress has been made in identifying optimal radiotherapy - drug combinations to improve treatment efficacy. Using molecular data...